Printer Friendly

S100B Protein concentrations in amniotic fluid are higher in monoamniotic than in diamniotic twins and singleton pregnancies.

S100B is an acidic calcium-binding protein of the EF-hand family present in the central nervous system, where it is located mainly in glial cells (1). It has been suggested that the protein is involved in various cellular functions, but precisely which is still a matter of debate. The protein has been found to act at physiologic concentrations as a cytokine with a neurotrophic role in experimental models, in cell cultures, and in biological fluids such as cord blood, peripheral blood, and urine (1-4). This hypothesis has been corroborated by measurements of S100B protein in amniotic fluid in the second trimester of pregnancy (5). The present work, following from an earlier study, investigates amniotic fluid S100B concentrations in twins.

We performed a case-control study (between January 1998 and June 2002) of 49 women with physiologic twin pregnancies (27 monoamniotic and 22 diamniotic) who underwent amniocentesis to exclude chromosomal abnormalities between the 15th and 18th weeks of gestation (mean, 16.5 weeks). The control group consisted of 490 singleton pregnancies matched for gestational age and weight at sampling and normal neonatal outcome (5 control fetuses for each twin fetus). Appropriate fetal growth was defined by the presence of ultrasonographic signs (when biparietal diameter and abdominal circumference were between the 10th and 90th percentiles) according to the normograms of Campbell and Thoms (6) and by postnatal confirmation of a birth weight between the 10th and 90th percentiles according to our population standards after correction for maternal height, weight, and parity and the sex of the newborns. Exclusion criteria included intrauterine growth retardation; gestational hypertension; diabetes and infections; fetal malformations; chromosomal abnormalities; maternal exposure to alcohol, cocaine, or smoke; perinatal asphyxia; and dystocia.

The local ethics committee approved the study protocol, and the parents of the fetuses examined gave signed and informed consent.

At the indicated times (15th-18th weeks of gestation), we collected 500 [micro]L of amniotic fluid from the amniotic cavity and immediately centrifuged it at 900g for 10 min; the supernatants were then stored at -70 [degrees]C until measurement. The S100B protein concentration was measured in all samples with use of a commercially available immunoluminometric assay (Lia-mat Sangtec 100; AB Sangtec Medical, Bromma, Sweden). According to the manufacturer's instructions, this assay distinguishes between the A1 and B subunits of the S100 protein and measures the [BETA]-subunit as detected by the three monoclonal antibodies SMST 12, SMSK 25, and SMSK 28. The ([BETA]-subunit of the S100 protein is known to be predominant (80-96%) in the human brain (7,8). Each measurement was performed in duplicate according to the manufacturer's recommendations, and the averages were reported. As indicated by the manufacturer, the limit of detection of the assay ([B.sub.o] + 3 SD) was 0.02 [micro]g/L, and the within- and between-assay imprecision (CV) was [less than or equal to] 5.5% and [less than or equal to] 10%, respectively, for concentrations of 0.28-4.17 [micro]g/L.

Data are expressed as mean (SD). The amniotic fluid S100B concentrations and neonatal characteristics were analyzed by Kruskal-Wallis one-way ANOVA and Mann-Whitney two-sided U-test when the data did not follow a gaussian distribution. Comparisons between proportions were performed with use of the Fisher exact test. The correlation between the concentrations of S100B in amniotic fluid and weeks of gestation was analyzed by linear regression analysis. A P value <0.05 was considered significant.

At birth all of the newborns showed normal clinical conditions, and no overt neurologic injuries were observed on discharge from the hospital. As expected, mean (SD) gestational age [35 (2) vs 38 (1) weeks] and weight at birth [2127 (231) vs 2936 (342) g] differed (P <0.05 for both) between twins (both monoamniotic and diamniotic) and control groups. There were no differences in Apgar scores at 1 and 5 min, and the incidences of caesarian section, respiratory distress syndrome, and neurologic abnormalities were superimposable in the two groups studied (P >0.05 for all). There were no significant differences in the groups of twins regarding mode of delivery, gestational age and weight at birth, or Apgar scores evaluated at the 1st and 5th min when the data were corrected for monoamniotic (group A) and diamniotic (group B) twins.

At sampling, all fetuses monitored appeared to meet ultrasound scanning parameters for appropriate growth. We observed no differences between controls and twins for gestational age [controls, 16.3 (1) weeks; twins, 16.4 (1) weeks; P >0.05], fetal weight [controls, 179 (22) g; twins, 184 (28) g; P >0.05], head circumference [controls, 131 (12) mm; twins, 133 (9) mm; P >0.05], biparietal diameter [controls, 114 (10) mm; twins, 116 (8) mm; P >0.05], or transverse cerebellum diameter [controls, 15.4 (0.7) mm; twins, 15.6 (0.9) mm; P >0.05]. Similarly, we found no significant differences in these parameters between group A and group B twins (P >0.05 for all).

S100B concentrations in amniotic fluid were higher in the twins [0.62 (0.46) [micro]g/L] than in the controls [0.53 (0.22) [micro]g/L; P <0.001]. Similarly, S100B concentrations in amniotic fluid were significantly higher in group A twins [1.06 (0.21) [micro]g/L] than in group B [0.51 (0.25) [micro]g/L] or the controls [0.53 (0.22) [micro]g/L; P <0.001 for all; Fig. 1A]. We found no statistical difference between group B twins and controls (P >0.05).

We found significant correlations between S100B in amniotic fluid and gestational age in both monoamniotic/ diamniotic twins (r = 0.56 and 0.52, respectively; Fig. 113) and controls (r = 0.23; P <0.001 for all)

Our results for the correlation between gestational age at sampling and S100B protein concentrations fit previous observations, offering additional support for normality reference curves in uncomplicated singleton and multiple pregnancies. The results for S100B concentrations in the amniotic fluid of controls also offer support for previously reported S100B values in the amniotic fluid of pregnant women with uncomplicated pregnancies and for the correlation between the protein concentrations and gestational age at sampling (5).

Our findings showing a higher (approximately double) concentration of S100B in amniotic fluid in physiologic monoamniotic pregnancies than in diamniotic twin or singleton pregnancies appear interesting. The data are consistent with a neurotrophic role for the protein (1-5) and support the hypothesis that each fetus releases a physiologically defined amount of the protein, in accordance with the role of S100B as a cytokine (1, 2), that appears to be more concentrated in relation to the volume of the amniotic sac, which is not usually twice as voluminous in twins as in singleton pregnancies. The source of much of the S100B present in the amniotic fluid could be the fetal nervous system, where the protein has been shown to be present at the ages investigated, albeit not at mature concentrations (9-12). In this respect, we cannot exclude the possibility that at least a part of the S100B present in monoamniotic twins is a consequence of compression of the fetuses in the sac.

Nonetheless, because different placental tissues contain S100B at concentrations that vary in relation to gestational age (13, 14), the possibility that the protein derives partly from the placenta must be taken into account. However, the higher concentrations of S100B in monoamniotic fetuses than in diamniotic and control fetuses seem to suggest a fetal rather than a placental origin for the protein in amniotic fluid, although the possibility that placental tissues produce a higher amount of neurotrophic S100B in cases of multiple pregnancies cannot be ruled out.

[FIGURE 1 OMITTED]

The possibility that S100B may be released, at least in part, from other sites in which it is concentrated, such as adipose tissue (15), could also be considered, although data on the presence of the protein in adipocytes at this stage of maturation are not available.

In conclusion, the present study offers a clue for the investigation of S100B dynamics in vivo, with special reference to a possible role of the protein as a cytokine involved in fetal brain maturation in both singleton and multiple pregnancies.

This work was partially supported by grants from Universita Cattolica del S. Cuore, Ministero dell'Universita e Ricerca Scientifica e Tecnologica, and Ministero della Salute (to Fabrizio Michetti), and from Consiglio Nazionale delle Ricerche and Ministero dell'Univerisita e Ricerca Scientifica e Tecnologica 2001 (to Diego Gazzolo). We also thank Sangtec Medical (Bromma, Sweden) and Byk Goulden Italia for supplying assay reagents.

References

(1.) Heizmann CW. [Ca.sup.2+]-binding S100 proteins in the central nervous system. Neurochem Res 1999;24:1097-100.

(2.) Haglid KG, Yang Q, Hamberger A, Bergman S, Widerberg A, Danielsen N. S100o stimulates neurite outgrowth in the rat sciatic nerve grafted with acellular muscle transplants. Brain Res 1997;69:196-201.

(3.) Gazzolo D, Vinesi P, Marinoni E, Di lorio R, Marras M, Lituania M, et al. S100B protein concentrations in cord blood: correlations with gestational age in term and preterm deliveries. Clin Chem 2000;46:998-1000.

(4.) Gazzolo D, Bruschettini M, Lituania M, Serra G, Gandullia E, Michetti F. S100B protein in urine is correlated with gestational age in healthy preterm and term newborns. Clin Chem 2001;47:1132-3.

(5.) Gazzolo D, Bruschettini M, Corvino V, Sarli R, Lituania M, Bruschettini PL, et al. S100B protein concentrations in amniotic fluid are correlated with gestational age and with cerebral ultrasound scanning parameters results in healthy fetuses. Clin Chem 2001;47:954-6.

(6.) Campbell S, Thorns A. Ultrasound measurements of the fetal head to abdomen circumference ratio in the assessment of growth retardation. Br J Obstet Gynaecol 1997;84:165-74.

(7.) Jensen R, Marshak DR, Anderson C, Lukas TJ, Watterson DM. Characterization of human brain S100 protein fraction: amino acid sequence of S1000. J Neurochem 1985;45:700-5.

(8.) Baudier J, Glasser N, Haglid K, Gerard D. Purification, characterization and ion binding properties of human brain S100o protein. Biochim Biophys Acta 1984;790:164-73.

(9.) Michetti F, Gazzolo D. S100B protein in biological fluids: a tool for perinatal medicine. Clin Chem 2002;48:2097-104.

(10.) Zuckerman JE, Herschman HR, Levine L. Appearance of a brain specific antigen (the S-100 protein) during human foetal development. J Neurochem 1970;17:247-51.

(11.) Lauriola L, Sentinelli S, Maggiano N, Michetti F, Cocchia D. Glial like cells in sympathetic neural crest derivatives during human embryogenesis. Detection by S100 immunohistochemistry. Dev Brain Res 1986;28:69-74.

(12.) Lauriola L, Coli A, Cocchia D, Tallini G, Michetti F. Comparative study by S100 and GFAP immunohistochemistry of glial cell populations in the early stages of human spinal cord development. Dev Brain Res 1987;37:251-5.

(13.) Tiu SC, Chan WY, Heizmann CW, Shafer BW, Shu SY, Yew DT. Differential expression of S100B and S100A6(1) in the human fetal cerebral cortex. Brain Res Dev Brain Res 2000;7:159-68.

(14.) Marinoni E, Di lorio R, Gazzolo D, Lucchini C, Michetti F, Corvino V, et al. Ontogenic localization and distribution of S-100/3 protein in human placental tissues. Obstet Gynecol 2002;99:1093-9.

(15.) Wijnberger LID, Nikkels PG, van Dongen AJ, Noorlander CW, Mulder EJ, Schrama LH, et al. Expression in the placenta of neuronal markers for perinatal brain damage. Pediatr Res 2002;51:492-6.

(16.) Michetti F, Dell'Anna E, Tiberio G, Cocchia D. Immunochemical and immunocytochemical study of S100 protein in rat adipocytes. Brain Res 1983; 262:352-6.

Diego Gazzolo, [l] Mario Lituania, [2] Matteo Bruschettini, [l] Pierluigi Bruschettini, [l] and Fabrizio Michetti [3]* (Departments of 'Pediatrics and 2 Obstetrics and Gynecology, Giannina Gaslini Children's University Hospital, I-16147 Genoa, Italy; [3] Institute of Anatomy and Cell Biology, University Cattolica del S. Cuore, Largo Francesco Vito 1, I-00168 Rome, Italy; * author for correspondence: fax 39-0630154813, e-mail fabrizio.michetti@ rm.unicattdt)
COPYRIGHT 2003 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Technical Briefs
Author:Gazzolo, Diego; Lituania, Mario; Bruschettini, Matteo; Bruschettini, Pierluigi; Fabrizio, Michetti
Publication:Clinical Chemistry
Date:Jun 1, 2003
Words:1960
Previous Article:Lamellar body count in amniotic fluid: a comparative study of four different hematology analyzers.
Next Article:Cytometric bead array to measure six cytokines in twenty-five microliters of serum.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |